Exact Sciences Corporation
Trial Pipeline
Falcon Real World Evidence Registry
NCT06589310
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
NCT06401421
CORRECT Study of Minimal Residual Disease Detection in Colorectal Cancer
NCT05210283
ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk
NCT05064553
Voyage: Real-World Impact of the Multi-target Stool DNA Test on CRC Screening and Mortality
NCT04124406
Home Usability Study of the SARS-CoV-2 (COVID-19) Test
NCT04395391
Detecting Cancers Earlier Through Elective Plasma-based CancerSEEK Testing
NCT04213326
Blood and Stool Sample Collection in Subjects With a Diagnosis of Colorectal Cancer or Colorectal Lesion: Act Fast
NCT03789162
Blood Collection Sub-Study for CRC Screening in Individuals 45-49 at Average Risk for CRC.
NCT03741166
Blood Sample Collection in Subjects With Pulmonary Nodules or CT Suspicion of Lung Cancer or Pathologically Diagnosed Lung Cancer
NCT03633006
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
NCT02419716
Therapeutic Areas
What the Pipeline for Exact Sciences Corporation Shows
According to the ClinicalTrials.gov registry, Exact Sciences Corporation is linked to 42 US clinical trials across every stage of research activity. Of those, 33 studies are currently recruiting — about 79% of the sponsor's indexed portfolio — and 6 are already marked complete, representing roughly 14% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Exact Sciences Corporation reports 0 late-stage studies (Phase 3 and Phase 4 combined) and 0 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Exact Sciences Corporation is Colorectal Cancer with 3 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.